GENUS LIFESCIENCES is a specialty pharmaceutical company focused on Metabolic, Oncology. Key products include POKONZA.
GENUS LIFESCIENCES's Key Drugs
GENUS LIFESCIENCES's core commercial portfolio centers on POKONZA, spanning Metabolic and Oncology — its most strategically important drugs approved in the last 15 years.
GENUS LIFESCIENCES's Recent FDA Approvals
New NDA/BLA approvals for GENUS LIFESCIENCES over the last two years — novel drugs only, excluding generics and label supplements.
GENUS LIFESCIENCES's Therapeutic Areas
GENUS LIFESCIENCES's approved drugs and pipeline span 2 therapeutic areas, led by Metabolic and Oncology, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
GENUS LIFESCIENCES's Top Competitors
GENUS LIFESCIENCES's closest competitors by therapeutic-area and drug-target overlap include Merck, Baxter, and Johnson & Johnson. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
GENUS LIFESCIENCES Pipeline Snapshot
Active clinical trials for GENUS LIFESCIENCES across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • POKONZA leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Metabolic pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling